Gamunex-C is indicated for the treatment of: - Primary humoral immunodeficiency disease (PIDD) in patients two years of age and older. - Idiopathic thrombocytopenic purpura (ITP) in adults and children. - Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. Gamunex-C is: - First and only USFDA approved for CIDP. - Approved to be infused with higher infusion rates (Up to 0.08 ml/kg/min). - Approved to be given over 2 days rather than 5 days.